Business
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2026On track for U.S. commercial launch of atacicept in mid-2026, pending regulatory approvalStrong balance sheet expected to be sufficient to fund operations beyond potential atacicept approval and U.S. commercial launch BRISBANE, Calif., May 07,
About this update from Vera Therapeutics, Inc.
[{"type":"image","alt":"Vera Therapeutics","displaySize":"","headline":null,"caption":"Vera Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/72a8e9e8ecc86f0d9732b38c0cd327c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Mlp5uKt6Zpy.D3U12h0qag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/72a8e9e8ecc86f0d9732b38c0cd327c5","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Mlp5uKt6Zpy.D3U12h0qag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/72a8e9e8ecc86f0d9732b38c0cd327c5","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2026","length":257,"tagName":"p"}]},{"val":[{"type":"text","content":"On track for U.S. commercial launch of atacicept in mid-2026, pending regulatory approval","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong balance sheet expected to be sufficient to fund operations beyond potential atacicept approval and U.S. commercial launch","length":128,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":474,"olType":false},{"type":"text","content":"BRISBANE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2026.","length":337,"tagName":"p"},{"type":"text","content":"“The team at Vera Therapeutics is focused on execution as we advance atacicept toward potential FDA accelerated approval in IgAN,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “During the first quarter, we made meaningful progress across key pre‑commercial activities, including in sales, marketing, market access, compliance, and commercial operations, to support a successful U.S. launch, pending regulatory approval. We are excited for atacicept to ...